semaglutide fda label Oral Gets Approval for CV Event Reduction in High-risk Diabetes Patients US FDA removes suicidal thoughts

Use at your own discretion

Semaglutide 1mg is a prescriber-directed weight-management medication option

In its phase 3 TRIUMPH-4 study, the company reported that its new triple-agonist injection, retatrutide, produced an average 28.7% reduction in body weight over 68 weeksa result that surpasses even the blockbuster Zepbound

Obesity affects over 1.9 billion people worldwide.[1]In 2024, global spend on anti-obesity medication exceeded $30 billion for the first time, which is over a ten-fold increase since 2020, as reported by IQVIA.[2]This is driven by an unprecedented and ever-increasing demand for appetite-suppressing drugs, with Novo Nordisk being a leader in the research, development and manufacture []